Aditi Chatterjee, PhD

• Research Associate, University of Maryland, Baltimore (2024–Present)

• Postdoctoral Fellow, University of Maryland, Baltimore (2019–2024)

• Postdoctoral Fellow, University of California, San Francisco (2018–2019)

• PhD, Biological Sciences (2018)
  CSIR–Central Drug Research Institute, Lucknow, India
  Thesis: Molecular and functional characterizations of protein tyrosine phosphatases and their prospective roles in subverting the growth and survival of mycobacteria

• MSc, Biotechnology (2010)
  LPU, Punjab, India

• BSc (Honors), Microbiology (2008)
  University of Burdwan, West Bengal, India

Dr. Aditi Chatterjee is a Research Associate at the University of Maryland, Baltimore, with over a decade of research experience spanning cancer biology, molecular signaling, and infectious diseases. Her work is centered on elucidating mechanisms of drug resistance and developing rational combination strategies to enhance therapeutic efficacy in acute myeloid leukemia (AML), particularly FLT3-ITD–driven disease. She has led innovative projects investigating kinase inhibitor resistance and has contributed to translational studies using primary patient-derived blood and bone marrow samples.

Dr. Chatterjee has extensive expertise in kinase and phosphatase signaling, genome editing, and functional genomics, with a strong foundation in biochemical and cell-based assays. Her research integrates molecular biology, flow cytometry, drug combination modeling, and proteomic approaches to dissect oncogenic survival pathways and identify vulnerabilities in resistant leukemia cells. In parallel, her earlier work established important mechanistic insights into antimicrobial resistance in Staphylococcus aureus and Mycobacterium tuberculosis, highlighting conserved signaling paradigms across cancer and infectious diseases.

She is an active contributor to the scientific community through peer review, editorial service, and institutional committees, and has a strong track record of high-impact publications. Dr. Chatterjee is committed to collaborative, interdisciplinary research and has mentored graduate students and postdoctoral fellows in advanced experimental design and translational research methodologies.

Acute Myeloid Leukemia (AML),FLT3-ITD signaling,Kinase inhibitor resistance,Targeted combination therapies,Drug resistance mechanisms

1. Aditi Chatterjee, Moaath K Mustafa Ali, Christopher M Bailey, Yuchen Liu, Donald Small, Catherine C Smith, Elie Traer, Yin Wang, Giovannino Silvestri, Maria R Baer. Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors. bioRxiv[Preprint]. 2025 Nov 24:2025.11.21.689510.doi: 10.1101/2025.11.21.689510.

2. Jonelle K. Lee, Aditi Chatterjee, Mario Scarpa, Christopher M Bailey, Sandrine Niyongere, Prerna Singh, Moaath K Mustafa Ali, Shivani Kapoor, Yin Wang, Giovannino Silvestri, Maria R. BaerPim kinase inhibitors increase gilteritinib cytotoxicity in FLT3-ITD acute myeloid leukemia through GSK-3β activation and c-Myc and Mcl-1 proteasomal degradation. Cancer Research Communications (2024) 4 (2): 431–445.

3. Aditi Chatterjee, Raymond Poon, Som S ChatterjeeStp1 loss of function promotes β-lactam resistance in Staphylococcus aureus that is independent of classical genes. Antimicrobial Agents and Chemotherapy (2021)Vol. 64, No. 6